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ARTICLE
Epigenetic Regulation of Human g-Glutamyl Hydrolase Activity
in Acute Lymphoblastic Leukemia Cells
Qing Cheng, Cheng Cheng, Kristine R. Crews, Raul C. Ribeiro, Ching-Hon Pui,
Mary V. Relling, and William E. Evans
g-Glutamyl hydrolase (GGH) catalyzes degradation of the active polyglutamates of natural folates and the antifolate
methotrexate (MTX). We found that GGH activity is directly related to GGH messenger RNA expression in acute lym-
phoblastic leukemia (ALL) cells of patients with a wild-type germline GGH genotype. We identiﬁed two CpG islands
(CpG1 and CpG2) in the region extending from the GGH promoter through the ﬁrst exon and into intron 1 and showed
that methylation of both CpG islands in the GGH promoter (seen in leukemia cells from ∼15% of patients with non-
hyperdiploid B-lineage ALL) is associated with signiﬁcantly reduced GGH mRNA expression and catalytic activity and
with signiﬁcantly higher accumulation of MTX polyglutamates (MTXPG4–7) in ALL cells. Furthermore, methylation of
CpG1 was leukemia-cell speciﬁc and had a pronounced effect on GGH expression, whereas methylation of CpG2 was
common in leukemia cells and normal leukocytes but did not signiﬁcantly alter GGH expression. These ﬁndings indicate
that GGH activity in human leukemia cells is regulated by epigenetic changes, in addition to previously recognized
genetic polymorphisms and karyotypic abnormalities, which collectively determine interindividual differences in GGH
activity and inﬂuence MTXPG accumulation in leukemia cells.
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Intracellular folates are required as cofactors in DNA syn-
thesis, repair, and methylation, and they are essential for
normal cellular growth and replication.1,2 Antifolates, such
as methotrexate (MTX), are competitive inhibitors of fo-
late-dependent enzymes and are widely used in the treat-
ment of many human cancers, including acute lympho-
blastic leukemia (ALL). Folates and most antifolates exist
intracellularly as more-active polyglutamated derivatives,
which are retained longer in cells because they are gen-
erally not substrates of export transporters.1 Hydrolytic
removal of g-linked polyglutamates, including folylpoly-
g-glutamates and antifolylpoly-g-glutamates, is catalyzed
by the lysosomal peptidase g-glutamyl hydrolase (GGH
[MIM 601509]).3
MTX is a major component of the curative treatment
of childhood ALL,4 and the extent of accumulation of its
active polyglutamates (MTXPG) determines its cytotox-
icity and inﬂuences treatment response in childhood
ALL.5 GGH converts long-chain MTXPG into shorter-
chain MTXPG and ultimately into MTX, which can be
efﬂuxed from cells.6,7 In children with nonhyperdiploid
B-lineage ALL (BNHD-ALL), GGH activity in leukemia cells
is inversely correlated with long-chain MTXPG accumu-
lation.8 Hyperdiploid B-lineage ALL (BHD-ALL) cells with
trisomy of chromosome 8 that contains a wild-type GGH
allele have signiﬁcantly higher GGH activity and accu-
mulate less MTXPG than do those with disomy 8.9
GGH activity and MTXPG accumulation in leukemia
cells are also affected by a substrate-speciﬁc function-
al genetic polymorphism in GGH, 452CrT (T127I,
rs11545078).8 This SNP alters GGH’s surface conformation
at the substrate-binding cleft and reduces its binding af-
ﬁnity to long-chain MTXPG. Among patients with the
same ALL subtype (e.g., BNHD-ALL, T-lineage ALL, or
BHD-ALL without an additional chromosome 8), 452CrT
was found at high frequency among patients with low
GGH activity, and it was not found in patients with high
GGH activity.8 However, there remains substantial inter-
individual variability in GGH activity that is not explained
by genetic polymorphism or karyotypic abnormalities.
Cancer has been linked to both genetic and epigenetic
changes.10 Epigenetic modiﬁcations, mainly DNA meth-
ylation at CpG dinucleotides, affect the regulation of gene
transcription without altering the gene’s sequence. Short
sequences rich in CpG dinucleotides (i.e., CpG islands)
are often found in the 5′ promoter region of genes and
can extend into the ﬁrst exon and sometimes into intron
1.10,11 Aberrant methylation of CpG islands is a common
feature of cancer cells,12,13 and methylated CpG islands
have been consistently detected in primary human acute
leukemia samples, sometimes with consequent silencing
of gene expression.13 In the current study, we examined
epigenetic modiﬁcations of GGH in leukemia cells and
normal leukocytes from pediatric patients with ALL and
identiﬁed two CpG islands in the promoter region ofGGH.
CpG island 1 (CpG1) was methylated in leukemia cells
but not in normal leukocytes, whereas CpG island 2
(CpG2) was methylated in both normal leukocytes and
leukemia cells. Methylation of CpG1 alone in leukemia
cells was associated with modest down-regulation of GGH
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Table 1. Primer Sequences
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
expression, whereas methylation in both CpG1 and CpG2
was associated with signiﬁcantly reduced GGH mRNA
expression and GGH catalytic activity. Our ﬁndings es-
tablish that epigenetic mechanisms alter GGH activity
and MTXPG accumulation in human leukemia cells via
methylation of CpG islands in the human GGH promoter
region.
Subjects and Methods
Patients and Pharmacologic Analyses
We studied 93 children (aged 21 years) who had newly diag-
nosed ALL and were enrolled in St. Jude Total Therapy XV pro-
tocols. We also studied six children (aged 21 years) who had
newly diagnosed acute myeloid leukemia (AML), had no struc-
tural aberrations on chromosome 8, and were enrolled in the
St. Jude AML-97 protocol. Of the 93 patients with ALL, 46 had
BNHD-ALL and 47 had either BHD-ALL ( ) or T-lineage ALLnp 31
( ). We had sufﬁcient ALL cells to determine both GGHnp 16
catalytic activity and mRNA expression in 40 of 46 patients with
BNHD-ALL. Of these 40 patients, 34 had a wild-type GGH ge-
notype for the SNP at position 452 (452CC), and 6 had a variant
GGH allele (452CT or 452TT genotype). Among the 31 patients
with BHD-ALL, 12 had trisomy of chromosome 8 in their leu-
kemia cells. The treatments and research protocols were approved
by the Institutional Review Board of St. Jude Children’s Research
Hospital, and informed consent was obtained from patients or
their guardians (or both) before enrollment. Patient assent was
also obtained when appropriate (from those aged14 years). The
diagnoses of ALL and AML were based on morphologic and
molecular analyses described elsewhere,14,15 and complete chro-
mosomal analysis was performed on leukemia cells from each
patient, according to the International System for Human Cy-
togenetic Nomenclature (ISCN 1995).16
Leukemia cells were isolated by applying a Ficoll-Hypaque gra-
dient to bone marrow aspirates obtained at diagnosis (median
97% blast cells), and GGH activity and MTXPG concentration
were measured as described elsewhere.8 Normal leukocytes were
isolated from peripheral blood samples obtained after the suc-
cessful completion of remission-induction therapy (on days 45–
48 after the start of treatment).
Gene Expression Analysis and Germline Genotyping
Genomic DNA and RNA were extracted from leukemia cells and
normal leukocytes by use of TriReagent (MRC). GGH germline
genotype was determined in 611 children with ALL by use of
leukocyte DNA as described elsewhere.8
Bymethods described elsewhere,17 total RNAwas processed and
hybridized to the HG-U133A oligonucleotide microarray (Affy-
metrix) according to the manufacturer’s protocol. We used the
default settings of the Affymetrix Microarray Suite software, ver-
sion 5 (MAS 5.0), to calculate scaled gene-expression values.GGH
expression was assessed by evaluating the Affymetrix expression
signal resulting from hybridization with probe set 203560_at.
GGH expression in leukemia cells was also measured by RT-PCR
(table 1) in a subset of patients.
Promoter Methylation Analysis
MethPrimer18 was used to predict promoter CpG islands and to
design primers for bisulﬁte sequencing and nested methylation-
speciﬁc PCR (NMSP) (table 1). Sodium bisulﬁte modiﬁcation was
performed using the CpGenome DNA Modiﬁcation Kit (Chem-
icon International) according to the manufacturer’s protocol,
with minor modiﬁcations to optimize performance. In brief, ge-
nomic DNA (100 ng for bisulﬁte sequencing and 40 ng for NMSP)
was denatured by incubation with NaOH (ﬁnal concentration 0.2
M) for 20 min at 50C. Sodium bisulﬁte solution (pH 5.0), freshly
prepared, was added, and the mixture was incubated at 50C for
14 h. The modiﬁed DNA was then treated with NaOH (ﬁnal con-
centration 0.3M) for 5min at room temperature, was precipitated
with ethanol, and then was resuspended in 25 ml TE buffer (10
mM Tris [pH 8] and 1 mM EDTA).
GGH promoter CpG1 and CpG2 were ampliﬁed using 3 ml bi-
sulﬁte-modiﬁed genomic DNA and 1# AmpliTaq Gold master
mix (Applied Biosystems) at an annealing temperature of 55C,
with 35 cycles for bisulﬁte sequencing and 20–25 cycles forNMSP.
For bisulﬁte sequencing, ampliﬁed CpG1 and CpG2 were sub-
jected to TA cloning (Invitrogen), and 110 clones were selected
for cycle sequencing. For NMSP, 1-ml aliquots of ampliﬁed frag-
ments were used in second-round PCR with 1# True Allele PCR
mix (Applied Biosystems) for 2 min at 50C and 10 min at 95C
followed by 25–40 cycles for 15 s at 95C and 1 min at 60C.
Genomic DNA isolated from a healthy individual whose GGH
promoter was unmethylated was used as a negative control, and
genomic DNA treated with SssI methylase (at 37C for 16 h and
65C for 20 min) was used as a positive (methylated) control.
Promoter Constructs and Luciferase Assays
Wild-type fragments of the entireGGH promoter (1002 to23),
CpG1 (1002 to 419) and CpG2 in the promoter region (418
to 23), were cloned from human Nalm6 ALL cells by use of the
TOPO TA cloning kit (Invitrogen). Reconstructed GGH promoter
(CpG1 and CpG2) was subcloned into the pGL3-Basic vector (Pro-
mega) from NheI to HindIII sites. CpG1, CpG2, or the entire GGH
promoter was removed from the vector by digestion with the
appropriate restriction enzyme (NheI plus BglII, BglII plusHindIII,
or NheI plus HindIII) and was incubated with 1 U/mg SssI meth-
ylase (New England Biolabs) and 200 nM S-adenosylmethionine
at 37C for 16 h and then at 65C for 20 min. Methylated CpG
island fragments and the remaining portions of the constructs
were religated after in vitro methylation. The ligation efﬁciency
was monitored by gel electrophoresis, and the ligated products
were extracted by gel puriﬁcation (Qiagen). To conﬁrm complete
methylation, reconstructed GGH promoter was restriction di-
gested with NheI and HindIII followed by BstUI digestion at 60C
for 1 h.
Nalm6 cells ( cells/ml) were transfected with 2 mg of62# 10
ﬁreﬂy luciferase promoter-reporter plasmid containing methyl-
ated CpG1 alone, methylated CpG2 alone, or methylated and
unmethylated entire promoter fragment, with 0.1 mg of phRL-TK
(Promega), by use of Lipofectamine 2000 (Invitrogen). Activities
of ﬁreﬂy and Renilla luciferases were measured 48 h after trans-
fection by use of the Dual-Glo luciferase assay system (Promega).
A pGL3-Basic vector without inserts and subcloned complete
GGH promoter were used as negative and positive controls, re-
spectively. Luciferase activity was calculated as the ratio of ﬁreﬂy
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Figure 1. Comparison of GGH activity in acute leukemia cells
with different genetic and lineage subtypes. GGH activity was mea-
sured in leukemia cells isolated from diagnostic bone marrow as-
pirates from pediatric patients with ALL ( ) or primary AMLnp 93
( ). Patients with ALL were grouped according to ALL lineage,np 6
DNA ploidy, number of chromosome 8, and whether the leuke-
mia cells contain the E2A-PBX1 or TEL-AML1 gene fusion. Differ-
ences between pairs were assessed using the exact Wilcoxon-Mann-
Whitney test. Boxes represent the 25%–75% quartiles, lines in the
boxes represent the median level of GGH activity, whiskers rep-
resent the nonoutlier range, and circles represent the outliers.
Figure 2. Relationship between GGH expression and GGH activity.
The legend is available in its entirety in the online edition of The
American Journal of Human Genetics.
to Renilla luciferase activities. Relative luciferase activity in the
experimental sample was expressed as a percentage of that in the
positive control.
Statistical Analysis
The objective of this study called for comparisons of continuous
phenotypes across two or more groups formed by methylation
status or genotype. The exact Kruskal-Wallis test was used to com-
pare the general differences in phenotype across more than two
groups; the exact Wilcoxon-Mann-Whitney test was used to com-
pare two genotype groups. Multivariate analysis of variance
(MANOVA) model was used to compare the effect of methylation
on expression and activity jointly. All computations were per-
formed using SAS (The SAS Institute).
Results
GGH Activity in ALL Cells
We measured GGH activity in ALL cells isolated from di-
agnostic bone marrow aspirates of children with newly
diagnosed ALL, and we found that GGH activity was sig-
niﬁcantly higher in T-lineage ALL cells ( ;np 93 Pp
) and in B-lineage ALL cells with trisomy 8 ( ;.0205 np 12
) than in B-lineage ALL cells with disomy 8P ! .0001
( ) (ﬁg. 1). In patients with B-lineage ALL, GGH ac-np 65
tivity was not signiﬁcantly associated with karyotypic ab-
normalities other than trisomy 8, such as presence of the
TEL-AML1 or E2A-PBX1 gene fusion, or other numerical
aberrations (ploidy differences). There was no signiﬁcant
difference in GGH expression between T-lineage ALL
( ) and B-lineage ALL cells with disomy 8 ( ;np 16 np 65
), a ﬁnding consistent with our previous results,19Pp .79
which indicates that other posttranslation factor(s) might
affect GGH activity in T-lineage ALL cells. Primary AML
cells had signiﬁcantly higher GGH activity than ALL cells
( ) (ﬁg. 1), consistent with a previous report.20Pp .0021
Relationship between GGH Activity and mRNA Expression
in Leukemia Cells
Because ALL lineage (T- vs. B-lineage), a GGH SNP
(452CrT), and chromosome number (trisomy 8) inﬂuence
GGH activity in ALL cells, we limited the current studies
to patients with BNHD-ALL (50 chromosomes), a wild-
type germline GGH genotype (452CC), and two copies of
chromosome 8 (this group represents ∼48% of B-lineage
ALL cases9). In these patients ( ), GGH activity innp 34
leukemia cells was highly variable (coefﬁcient of variation
51.5%; activity range 3.8–29.8 pmol/min/mg protein), and
this variability was signiﬁcantly explained by the level of
GGH mRNA expression ( ; ) (ﬁg. 2).2P ! .0001 R p 0.49
To determine whether SNPs in theGGH promoter region
and 3′ UTR affect GGH expression and activity, we se-
quenced the GGH promoter region and exon 9 in patients
with BNHD-ALL who had high or low GGH activity
( ). Excluding the 3′ UTR SNP 1102ArG,8 we foundnp 9
the GGH promoter SNPs 1187GrA (dbSNP accession
number rs11988534), 679CrT (rs3758147), 649GrA
(rs2736676),605CrG (rs28365060),424CrA (rs719236),
401CrT (rs3758149),354GrT (rs719235), and124TrC
(rs11545076) (numbered relative to the A of the transla-
tion start codon at nt 1) in ALL cells with high GGH
activity and in cases with low GGH activity. However, in
611 children with ALL, the 3′ UTR SNP 1102ArG was in
high linkage disequilibrium with 452CrT (in whites
[ ], in African Americans [ ], and in all othernp 459 np 102
patients [ ], for each test, calculated usingnp 50 P ! .001
Haplotype procedure [SAS/Genetics]). Using primers that
ampliﬁed the entire GGH coding region (table 1), we did
not ﬁnd any evidence of GGH splice variation in ALL cells
(ﬁg. 2B).
GGH Promoter CpG Islands and Their Effect on GGH
mRNA Expression
We identiﬁed two CpG islands within the 5-kb region
around exon 1 of the human GGH gene, including the 2-
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Figure 3. CpG islands in the GGH promoter region. A, Two CpG islands in the GGH 5′ promoter region extend into intron 1. The CpG1
and CpG2 regions (shaded areas) are indicated relative to the A of the translation start codon, deﬁned as nt 1. B, Sequence of the
GGH promoter region (nt 905 to 118) of each allele in the Nalm6 cell line and primary leukemia cells from ﬁve cases of ALL,
determined by bisulﬁte sequencing. GGH promoter methylation was conﬁrmed by NMSP in all ﬁve cases (data not shown). Each box
represents a CpG dinucleotide; methylated CpG sites are blackened; unmethylated CpG sites are unblackened. The polymorphisms at nt
649, 249, and 209 were used to deﬁne allelic methylation. C, Regulation of transcriptional activity of GGH promoter by selective
in vitro methylation of CpG islands in the GGH promoter region. The left panel shows a schematic diagram of the individually methylated
CpG islands within GGH promoter constructs linked to a luciferase reporter. Methylated CpG island fragments are blackened; unmethylated
fragments are unblackened.
kb 5′ upstream regulatory region. These two CpG islands,
at nt 790 to 442 (CpG1) and 369 to 245 (CpG2) (ﬁg.
3A), have a GC content 160% and a CpG density per
100 bp 170%. CpG1 is conﬁned to the GGH promoter
region, whereas CpG2 extends from the GGH promoter
region21 through the ﬁrst exon and into intron 1. A search
of the GenBank database revealed four “H.sapiens CpG
island DNA genomicMse1 fragments” (accessionnumbers
Z57223, Z57224, Z61329, and Z61330) in the region of
GGH CpG1 (ﬁg. 3A).
To determine the distribution of methylation in the
GGH promoter CpG islands, we analyzed the GGH pro-
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moter by using bisulﬁte-modiﬁed genomic DNA isolated
from bone marrow leukemia cells and from the human
ALL cell line Nalm6. We observed hypermethylation of
both CpG1 and CpG2 in GGH of Nalm6 cells (ﬁg. 3B) but
found that methylation was restricted to one GGH allele
in these cells (the G allele for SNP 649GrA). Consistent
with this ﬁnding is that Nalm6 cells have relatively low
GGH activity (6.9 pmol/h/mg protein).7 We also observed
methylation in CpG1 and CpG2 in leukemia cells from
two patients (cases 17 and 43) whose GGH mRNA ex-
pression array signals (707 and 831, respectively) were in
the lowest quartile among the patients studied. In these
two cases, the GGH promoter was methylated in the A
allele for SNP 649GrA. None of the three patients with
high GGH expression levels in their leukemia cells (array
expression signals were between 3,968 and 4,421) had
methylation in CpG1, but we observed methylation in
CpG2 alone in one patient (case 44).
To further assess the role of CpG island methylation in
regulating GGH expression, we reconstructed GGH pro-
moters with one or both CpG islands methylated, and we
measured promoter activity by a promoter luciferase assay,
as described in the “Subjects andMethods” section.Meth-
ylation of CpG1 alone reduced transcription by 88.4%
(relative luciferase activity ), whereasmeth-21.4%23.3%
ylation of CpG2 alone reduced transcription by only
26.9% (relative luciferase activity ) (ﬁg.77.9% 36.2%
3C). Promoter activity was essentially eliminated bymeth-
ylation of the entire GGH promoter region (CpG1 and
CpG2) (ﬁg. 3C).
GGH Promoter Methylation and Its Regulation of GGH
Expression in Leukemia Cells
Using NMSP, we analyzed the GGH promoter in leukemia
cells isolated from diagnostic bone marrow aspirates ob-
tained from 40 patients with BNHD-ALL. GGH mRNA ex-
pression in these same leukemia cells was measured by
Affymetrix microarray analysis. We detected methylated
GGH CpG1 in leukemia cells from 11 patients (28%), in-
cluding 6 (15%) with methylation in both CpG1 and
CpG2 (ﬁg. 4A). Methylated CpG2 alone was detected in
leukemia cells from 16 patients (40%). Leukemia cells in
which both CpG1 and CpG2 were methylated showed
signiﬁcantly lower GGH expression (2.1-fold reduction)
and catalytic activity (2-fold reduction) ( ;np 40 Pp
, by one-way MANOVA) when compared with leu-.003
kemia cells having only one or no CpG island methylated
(ﬁg. 4B). There was no correlation between methylation
of CpG2 alone and GGH expression or GGH activity (data
not shown). Compared with leukemia cells without GGH
promoter methylation or with methylation of CpG2
alone, those with methylated CpG1 alone expressed sig-
niﬁcantly less GGH (1.5-fold reduction) ( ;np 34 Pp
, by exact Wilcoxon-Mann-Whitney test), but the.0003
difference in GGH catalytic activity did not reach statis-
tical signiﬁcance ( ; , by exact Wilcoxon-np 34 Pp .16
Mann-Whitney test).
Leukemia Cell–Speciﬁc Methylation in GGH CpG1
We analyzedGGH promoter methylation in paired normal
peripheral blood leukocytes and leukemia cells obtained
from 22 patients, including 11 whose leukemia cells con-
tained methylated CpG1. None had methylated CpG1 in
their normal leukocytes (ﬁg. 5A). In contrast, CpG2meth-
ylation was found in normal leukocytes and in leukemia
cells (CpG2 methylation was found in normal leukocytes
of 36.4% of patients and in leukemia cells of 55% of pa-
tients) (ﬁgs. 4A and 5A).
We also analyzed GGH promoter methylation status in
leukemia cells isolated from diagnostic bone marrow as-
pirates from six children with primary AML. GGH CpG2
was methylated in the AML cells of three patients, but
none of the six patients had methylated CpG1 in their
AML cells (ﬁg. 5B).
Comparison of GGH Expression in Leukemia Cells and
Normal Leukocytes from Patients with ALL
To determine the effect of GGH promoter methylation on
GGH expression in normal leukocytes and leukemia cells,
we measured GGH expression levels in normal leukocytes
and leukemia cells from 17 children with BNHD-ALL by
using Affymetrix expression arrays. In 10 of 12 patients
whose leukemia cells did not contain methylated CpG1
(group 3, ﬁg. 5C), GGH was more highly expressed (by a
factor of 1.6–5.4) in leukemia cells than in the normal
leukocytes; in the remaining 2 patients, GGH expression
levels were similar in normal leukocytes and leukemia
cells. In contrast, in patients in whose leukemia cells both
CpG1 and CpG2 were methylated (group 1, ﬁg. 5C), GGH
was more highly expressed (by a factor of 2.1–5.3) in nor-
mal leukocytes than in leukemia cells. Among patients
with only CpG1 methylated in their leukemia cells (group
2, ﬁg. 5C), there was not a consistent difference in GGH
expression between leukemia cells and normal leukocytes.
GGH expression was not up-regulated in patients whose
normal leukocytes lacked CpG2 methylation (cases 7, 24,
25, and 29), consistent with in vitro results showing that
methylation in CpG2 alone does not affect GGH expres-
sion. These ﬁndings indicate that epigenetic modiﬁcation
of the entire GGH promoter occurs in leukemia cells but
not in normal leukocytes and further demonstrate that
methylation in both CpG islands is associated with the
greatest reduction in GGH expression. (We calculated the
ratio of GGH expression in ALL cells to that in normal
leukocytes for each patient and used this ratio in a three-
group comparison: ; , by exact Kruskal-np 17 Pp .002
Wallis test.)
Genetic Factors Altering GGH Activity in Leukemia Cells
As depicted in ﬁgure 6, three distinct genetic factors were
found to inﬂuence interindividual differences in GGH ac-
tivity in leukemia cells: chromosomal abnormalities (tri-
somy 8), genetic polymorphism (SNP 452CrT), and
epigenetic modiﬁcation (promoter methylation). These
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Figure 4. GGH promoter methylation status in ALL cells. A, NMSP analysis of the GGH promoter in leukemia cells from 40 patients
with BNHD-ALL. Two sets of primers were used to analyze the methylation status of GGH promoter CpG1 and CpG2. M p methylated
PCR products; N p negative (unmethylated) control; P p positive (methylated) control; U p unmethylated PCR products. B, Hyper-
methylation of both CpG islands in the GGH promoter was associated with down-regulated GGH expression. GGH activity, RNA expression
(Affymetrix array signal), and promoter methylation were measured in leukemia cells obtained at diagnosis from 40 children with BNHD-
ALL. The germline genotype of GGH at nt 452 (CrT) was assessed by examining genomic DNA isolated from normal peripheral leukocytes
from the same patients. Met p methylated; un-Met p unmethylated.
factors result in signiﬁcant differences in GGH activity in
leukemia cells from different subgroups of patients exhib-
iting these genetic and epigenetic differences ( ;np 49
, by exact Kruskal-Wallis test).P ! .0001
Because MTXPG accumulation in ALL cells is signiﬁ-
cantly inﬂuenced by ALL lineage and DNA ploidy and by
chromosomal translocations creating either the TEL-
AML1 or the E2A-PBX1 gene fusion,19 we compared GGH
activity and MTXPG accumulation in BNHD-ALL cells
not carrying the TEL-AML1 or E2A-PBX1 gene fusion,
a subtype that arises in ∼36% of cases of childhood
ALL.22 In these cells, methylation of the two CpG is-
lands in the GGH promoter was associated with signif-
icantly reduced GGH mRNA expression, reduced GGH
catalytic activity, and increased MTXPG accumulation
after in vivo treatment with 1 g/m2 intravenous MTX19
(ﬁg. 6).
Discussion
Because MTXPG accumulation in leukemia cells is a de-
terminant of the in vivo antileukemic effects of MTX,4,5,23
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Figure 5. GGH promoter methylation status in normal leukocytes and AML cells. A, NMSP analysis of the GGH promoter in normal
peripheral leukocytes (white blood cells [WBC]) isolated from 22 children with ALL. M p methylated CpG island; U p unmethylated
CpG island. B, NMSP analysis of the GGH promoter in leukemia cells isolated from six children with primary AML. C, Comparison of GGH
expression in leukemia cells (ALL) and normal leukocytes (WBC) from patients with ALL ( ). Group 1 includes patients whosenp 16
leukemia cells contained methylated CpG1 and CpG2; group 2, patients whose leukemia cells contained methylated CpG1 but not
methylated CpG2; and group 3, patients in whose leukemia cells CpG1 was not methylated. CpG1 was not methylated in the normal
leukocytes (WBC) of all patients.
we and others have focused on elucidating mechanisms
underlying the highly variable accumulation of MTXPG
in leukemia cells.7,24,25 We have already documented sig-
niﬁcantly differential expression of the genes encoding
reduced folate carrier (SLC19A1 [MIM 600424]); breast
cancer resistance protein (ABCG2 [MIM 603756]); ATP-
binding cassette, subfamily C, member 1 (ABCC1 [MIM
158343]); and folylpolyglutamate synthetase (FPGS [MIM
136510]) as a mechanism underlying differences in
MTXPG accumulation among some subtypes of ALL.19 We
have also shown that the catalytic activity of GGH in ALL
cells exhibits substantial interindividual differences that
are inﬂuenced by the number of copies of chromosome
8 containing a wild-type GGH allele9 and that GGH activ-
ity is inversely related to accumulation of long-chain
MTXPG in BNHD-ALL cells.8 However, before now, we did
not know what mechanism is responsible for differences
in GGH mRNA expression and catalytic activity in ALL
cells of patients with a diploid wild-type GGH genotype.
Here, we report epigenetic mechanisms controlling GGH
expression and catalytic activity in B-lineage ALL cells
containing two wild-type GGH alleles. We found signiﬁ-
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Figure 6. GGH phenotype, GGH genotype, and MTXPG accumulation. A, Genetic and epigenetic factors affecting GGH activity in leukemia
cells from patients with ALL. Overall comparison was performed using the exact Kruskal-Wallis test ( ; ). Pairwisenp 49 P ! .0001
comparison was performed using the exact Wilcoxon-Mann-Whitney test. WT p wild type. B, Comparison of GGH activity and MTXPG
accumulation in BNHD-ALL cells without the E2A-PBX1 or TEL-AML1 gene fusion. Boxes represent the 25%–75% quartiles, lines in the
boxes represent the median level, whiskers represent the nonoutlier range, and circles represent the outliers.
cant concordance between GGH activity and GGH mRNA
expression in leukemia cells from these patients. Further-
more, we observed methylation spanning the entire GGH
promoter region in leukemia cells of ∼15% of pediatric
patients with ALL and its concordance with signiﬁcantly
reduced GGH mRNA expression and catalytic activity.
Moreover, we showed that this was associated with higher
intracellular MTXPG concentrations after in vivo treat-
ment with MTX.
DNA methylation is an important mechanism regulat-
ing gene expression, and it is required for normal mam-
malian development.26–28 Alteration in DNA methylation
is a hallmark of cancer10,29,30 and may be observed as a loss
of global methylation or as a gain of methylation of se-
lected CpG islands, either of which can result in alteration
of the expression of hundreds of genes.12,13,31We identiﬁed
two CpG islands in the region extending from the GGH
promoter through the ﬁrst exon and into intron 1. To
perform population screening for GGH promoter meth-
ylation status, we designed an NMSP that requires as little
as 40 ng of genomic DNA from each patient sample. We
conﬁrmed GGH promoter methylation status in primary
leukemia cells and a BNHD-ALL cell line by sequencing
bisulﬁte-treated samples. We found that methylation of
CpG1 has a much greater effect on GGH expression than
does methylation of CpG2 and that methylation of both
CpG islands has the most pronounced effect on GGH
expression.
Allele-speciﬁc methylation has been observed in CpG
islands of imprinted genes.27,32 In the present study, how-
ever, methylation of CpG1 was speciﬁc to ALL cells and
occurred in the leukemia cells of 28% of children with
ALL, but it was not found in normal leukocytes from the
same patients. Methylation in CpG1 was also not detected
in leukemia cells from children with primary AML, a form
of leukemia that is less sensitive to MTX therapy. Fur-
thermore, we identiﬁed four “H.sapiens CpG island DNA
genomic Mse1 fragments” in GenBank that are homolo-
gous to GGH CpG1. These CpG island genomic DNA MseI
fragments are GC-rich chromosomal fragments that are
not methylated in primary, normal blood cells but are
methylated after in vitro treatment with methylase.33 A
library of CpG island genomic DNA MseI fragments has
been used to identify hypermethylated CpG islands in
cancer cells,34 but this has not been reported for GGH.
Consistent with our data is that no evidence exists that
GGH is an imprinted gene,27,32 and no imprinted genes
have been reported in the locus around the human GGH
coding region. Although GGH promoter methylation was
restricted to the G allele for SNP649GrA in Nalm6 cells,
methylation of the A allele was observed in primary ALL
cells from two of ﬁve patients (ﬁg. 3B).
The GGH promoter contains multiple transcriptional
start sites,21 all in the CpG2 region. However, we found
that methylation in GGH CpG1 has a more pronounced
effect on GGH expression (down-regulation) than does
methylation in CpG2. Methylation in CpG2was common
in leukemia cells and normal leukocytes from patients
with ALL, but it occurred at a somewhat higher frequency
in the leukemia cells. However, there was no relationship
between CpG2 methylation status and GGH expression in
ALL cells, and an absence of CpG2 methylation in normal
cells was not associated with higher GGH expression. This
ﬁnding is consistent with earlier reports that a high level
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of methylation around a transcriptional start site does not
always block transcription, especially for genes with mul-
tiple transcriptional start sites.35
Hypermethylation of CpG islands in cancer exhibits
heterogeneity both within the same tumor types and
among different tumor types.36,37 Methylated CpG islands
are often, but not always, associated with transcriptional
silencing.38,39 A recent study suggested that aberrantmeth-
ylation of CpG islands in malignancy might be less fre-
quent than expected, because only a small set of pro-
moters was differentially methylated in normal and
transformed human cells.39 Our study has revealed that
aberrant methylation in cancer cells can occur in speciﬁc
CpG islands (e.g., GGH CpG1) but not in other CpG is-
lands (e.g., GGH CpG2) within the same gene promoter
region. Furthermore, the present ﬁndings indicate that
cancer-speciﬁc CpG-island promoter methylation can
preferentially target CpG islands that have an effect on
gene expression (i.e., CpG1wasmethylated only in cancer
cells, whereas CpG2 was methylated in cancer and normal
cells). Therefore, a global assessment of methylation pro-
ﬁle—for example, by use of restriction landmark genomic
scanning40 or an oligonucleotide microarray-based meth-
ylation analysis41—would need to be performed in a man-
ner that permits one to determine whether methylation
in speciﬁc CpG islands (certain promoter regions) of a
given gene is associated with altered gene transcription or
cancer-cell phenotype (e.g., enzyme activity). An array
based on a CpG island library created by isolation of ge-
nomic fragments that contain CpG dinucleotide regions
that are poorly methylated in normal tissue has been used
as a genomewide method of detecting cancer-speciﬁcCpG
island methylation.33,42 Consistent with our ﬁndings, this
CpG island library contains the CpG1 region but not the
CpG2 region from the GGH promoter region.
Mechanisms by which CpG islands are hypermethy-
lated in cancer have not been fully elucidated. CpG island
methylation in cancer cells may be blocked by the binding
of the transcription factor Sp1,43,44 and it has been sug-
gested that a boundary sequence separating methylated
and unmethylated promoter regions exists.45,46 Recent
studies have indicated that DNA methylation in cancer
cells can be induced by micro-RNAs.47,48 De novo meth-
ylation in cancer cells has been suggested to start from a
methylation “hotspot” consisting of several nonadjacent
CpG sites. These hotspots are methylated in both normal
and cancer cells, and they serve as a starting point for
CpG island hypermethylation in cancer cells.35 Because
we found that methylation frequently occurs in GGH
CpG2 in both leukemia cells and normal leukocytes and
that both CpG1 and CpG2 are methylated on a single
allele, it is conceivable that methylation in CpG2 serves
as the seeding point from which de novo methylation of
the entire GGH promoter occurs in leukemia cells. How-
ever, the ﬁnding that the leukemia cells of several patients
had GGH promoter methylation of only CpG1 suggests
that leukemia cell–speciﬁc methylation of CpG1 arises by
another mechanism. Further study is needed to determine
whether methylation of a particular allele is a selective
process. Our ﬁndings that none of theGGHpromoter SNPs
examined was associated with altered GGH mRNA ex-
pression and that either GGH allele (G or A at nt 649)
can be methylated in primary ALL cells indicate thatGGH
promoter SNPs are not the driving force for single-allele
methylation.
Epigenetic silencing of genes that determine tumor in-
vasiveness, growth patterns of tumors, and tumor-cell
apoptosis12,29 may also affect the expression of drug-
metabolizing enzymes, thereby providing an additional
genetic mechanism in pharmacogenomics. Trisomy 8 that
contains wild-type GGH could be used as a ﬁrst parameter
to deﬁne a subgroup of ALL with higher GGHactivity than
that of the ALL subgroupwith disomy 8.9 AmongB-lineage
ALL cells containing disomy 8, epigenetic modiﬁcation
(methylation in both CpG1 and CpG2) had a more pro-
nounced effect on GGH activity than did the 452CrT SNP
(ﬁg. 4B). ALL cells in which both CpG1 and CpG2 were
methylated showed more than twofold lower GGH ex-
pression andGGH activity than did all the others.Wehave
shown elsewhere that the GGH SNP 452CrT changes the
protein surface conformation at the end of substrate-bind-
ing cleft and reduces binding afﬁnity with long-chain
MTXPG.8 This SNP signiﬁcantly lowers but does not abol-
ish catalytic activity and has a much less pronounced ef-
fect on GGH activity than does hypermethylation of the
GGH promoter.
Because numerous DNA changes, such as chromosomal
aberration and epigenetic modiﬁcation, are often cancer-
cell speciﬁc, germline genotyping does not always fully
assess quantitative differences in cancer genomes or can-
cer-cell phenotypes. Unequivocal elucidation of cancer-
cell pharmacogenomics may therefore require consider-
ation of the special features of the cancer-cell genome.9,49
Indeed, we show that GGH activity in human leukemia
cells is determined by epigenetic changes as well as germ-
line genetic polymorphisms and karyotypic abnormalities
in leukemia cells, which together account for a substantial
proportion of interindividual differences in GGH activity
and MTXPG disposition in human ALL cells (ﬁg. 6). The
current ﬁndings are important because they show that
multiple genomic mechanisms can control the expression
and function of a single gene in cancer cells and thereby
determine the pharmacogenomics of anticancer agents.
Our results also indicate that genetic and epigenetic
changes can have differing or additive effects on phar-
macogenetics of an anticancer drug in cancer cells. In this
study, we report substantial interindividual variability in
GGH activity and MTXPG disposition in human ALL cells
and that this variability is determined by multiple genetic
and epigenetic mechanisms. It has been reported that un-
detectable GGH mRNA expression and GGH protein are
associated with good prognosis of pulmonary neuroen-
docrine tumors50 and that high accumulation of MTXPG
in ALL cells is associatedwith better treatment response.5,23
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It will be important to extend these studies to larger co-
horts of patients, in which the effects of these epigenetic
changes on MTX activity and treatment outcome can be
more fully elucidated. The current studies are an impor-
tant foundation for future studies to deﬁne the utility of
these genetic, karyotypic, and epigenetic factors for in
dividualizing MTX therapy for ALL on the basis of
pharmacogenomics.
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